Evidence map›Paper›PMID 24875783›Full record

ArticlePloS one2014

The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.

Haitao Pan, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, Jielai Xia

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.Journal of the Royal Statistical Society. Series C, Applied statistics · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haitao PanSchool of Statistics, Xi'an University of Finance and Economics, Xi'an, China.
Cailin ZhuDepartment of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Feng ZhangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Shemin ZhangSchool of Statistics, Xi'an University of Finance and Economics, Xi'an, China.
Wenhong ZhangSchool of Statistics, Xi'an University of Finance and Economics, Xi'an, China.
Chanjuan LiDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.
Ling WangDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.
Jielai XiaDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Grade information has been considered in Yuan et al. (2007) wherein they proposed a Quasi-CRM method to incorporate the grade toxicity information in phase I trials. A potential problem with the Quasi-CRM model is that the choice of skeleton may dramatically vary the performance of the CRM model, which results in similar consequences for the Quasi-CRM model. In this paper, we propose a new model by utilizing bayesian model selection approach--Robust Quasi-CRM model--to tackle the above-mentioned pitfall with the Quasi-CRM model. The Robust Quasi-CRM model literally inherits the BMA-CRM model proposed by Yin and Yuan (2009) to consider a parallel of skeletons for Quasi-CRM. The superior performance of Robust Quasi-CRM model was demonstrated by extensive simulation studies. We conclude that the proposed method can be freely used in real practice.

Indexed as

Bayes TheoremMaximum Tolerated DoseModels, StatisticalAlgorithmsAntineoplastic AgentsClinical Trials, Phase I as TopicComputer SimulationHumansNeoplasmsAntineoplastic Agents

Identifiers

PMID24875783
PMCPMC4038518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.